100522-09-6

Upstream product

• 107100-61-8 2-(4-isopropyl-phenyl)-1,1-dimethyl-ethyl isocyanate 
• 101775-55-7 3-(4-isopropyl-phenyl)-2,2-dimethyl-propionic acid amide 
• 2051-18-5 4-isopropylbenzyl chloride 
• 113037-52-8 3-(4-isopropyl-phenyl)-2,2-dimethyl-1-phenyl-propan-1-one 

Downstream Products

• 868125-19-3 6-benzyloxy-8-{1-hydroxy-2-[2-(4-isopropyl-phenyl)-1,1'-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one 
• 198225-89-7 N-(2-Hydroxy-3-phenoxypropyl)-1,1-dimethyl-2-(4-isopropylphenyl)ethylamine Hydrochloride 

Relevant academic research and scientific papers

Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists

Novel β2-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the β2-adrenoceptor with a high β1/β2-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the β2-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h.

Aerosol formulation for the inhalation of beta-agonists

The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1 wherein the groups R1, R2, R3 and X? may have the meanings given in the claims a

Method of using calcilytic compounds

The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.